Savara Inc. - SVRA STOCK NEWS

Savara Inc. (Nasdaq: SVRA) announced that its pivotal Phase 3 IMPALA-2 trial evaluating molgramostim for autoimmune Pulmonary Alveolar Proteinosis is on track, with top-line data expected by the end of Q2 2024. Following a positive review from the Independent Data Monitoring Committee, the trial proceeds unmodified. The company also reported a net loss of $10.3 million for Q4 2022, maintaining a stable loss per share of $(0.07), and ended 2022 with $125.9 million in cash. Savara aims to launch a global aPAP market development campaign in 2H23 and believes it is sufficiently capitalized through 2025.

Savara Inc. (NASDAQ: SVRA) announced its management team's participation at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 1:20pm ET. A live webcast of the presentation will be available on Savara's website and archived for 90 days.

The company focuses on rare respiratory diseases and is in Phase 3 development of its lead program, molgramostim nebulizer solution, targeting autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via the investigational eFlow® Nebulizer System, developed in collaboration with PARI Pharma GmbH.

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced the granting of inducement awards to Robert M. Lutz, its new Chief Operating Officer, who joined on February 13, 2023. The award includes options to purchase 350,000 shares and RSUs for 140,000 shares, under the Savara 2021 Inducement Equity Incentive Plan. The options have an exercise price of $2.53 per share, equal to the closing price on the grant date, and vest quarterly over ten years. The RSUs fully vest after two years of employment. Savara focuses on rare respiratory diseases, with its lead program in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced key appointments to its leadership team, including Rob Lutz as Chief Operating Officer, Scott Wilhoit as Executive Vice President, Global Commercial, and Dave Lowrance as Chief Financial and Administrative Officer. The company is focused on completing enrollment for the IMPALA-2 Phase 3 trial of molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis (aPAP), aiming to deliver top-line results by the end of Q2 2024. These changes underscore Savara's commitment to advancing its rare respiratory disease therapies.

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, announced on January 17, 2023 that it granted inducement awards to two new employees. The awards consist of options to purchase a total of 195,000 shares of common stock and restricted stock units (RSUs) covering 60,000 shares. The options have an exercise price of $1.89 per share, equal to the closing stock price on the grant date. Each option vests quarterly over a 10-year term, while the RSUs fully vest two years after the new employees' start date. The awards are part of Savara's 2021 Inducement Equity Incentive Plan.

Savara Inc. (NASDAQ: SVRA), focused on rare respiratory diseases, announced an employee inducement award granted to Dr. Raymond Pratt, who joined as Chief Medical Officer on November 10, 2022. This award includes options to purchase 375,000 shares and restricted stock units for 150,000 shares, made under the 2021 Inducement Equity Incentive Plan. The option exercise price is $1.43, equivalent to the closing price on the grant date. Options vest quarterly over four years, while RSUs fully vest after two years, contingent on continued employment.

Savara Inc. (SVRA) reported its financial results for Q3 2022, highlighting a net loss of $10.4 million, consistent with the previous year. Research and development expenses rose by 24.8% to $8.2 million, driven by costs associated with the ongoing Phase 3 IMPALA-2 trial for molgramostim, an inhaled biologic for aPAP. The company ended the quarter with approximately $134 million in cash, expected to sustain operations through 2025. Additionally, Savara announced the appointment of Raymond Pratt, M.D. as Chief Medical Officer.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced its participation in three upcoming healthcare conferences. These include the Jefferies London Healthcare Conference on November 16, 2022, the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022. Each event will feature corporate presentations and a fireside chat. Webcasts of these presentations will be archived on Savara's website for 90 days.

Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced the grant of inducement awards to three new employees on September 13, 2022. These awards include options for 190,000 shares and RSUs for 75,000 shares, part of the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $1.46 per share and vest quarterly over 10 years. Savara focuses on rare respiratory diseases, with its lead program, molgramostim, in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).